Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma

International Journal of Cancer

Volumn 71, Issue 1, 1997, Pages 59-63

  Morecki, S ^a   Moshel, Y ^a   Gelfend, Y ^a   Pugatsch, T ^a   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; BONE MARROW; CHIMERA; FEMALE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASM TRANSPLANTATION; SURVIVAL RATE;

EID: 0030887390     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970328)71:1<59::AID-IJC11>3.0.CO;2-4     Document Type: Article

References (23)

1. CONCHA, A., CABRERA, T., RUIZ-CABELLO, F. and GARRIDO, F., Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int. J. Cancer, 6, 146-154 (1991).
2. + T lymphocytes. J. Immunol., 148, 1985-1992 (1992).
3. DE LA SELLE, V., MICONNET, I., GILBERT, D. and BRULEY ROSSET, M., Peripheral tolerance to host minor histocompatibility antigens in radiation bone marrow chimeras abrogates lethal GVHD while preserving GVL effect. Bone Marrow Transplant., 16, 111-118 (1995).
4. DEXTER, D.L., KOWALSKI, H.M., BLAZAR, B.A., FLIGIEL, Z., VOGEL, R. and HEPPNER, G., Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res., 38, 3174-3181 (1978).
5. FALKENBURG, J.H.F., FABER, L.M., VAN DEN ELSHOUT, M., VAN LUXEMBURGHEUS, S.A.P., HOOFTMAN-DEN UTTER, A., SMIT, W.M., VOOGT, P.J. and WILLEMZE, R., Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. J. Immunother., 14, 305-309 (1993).
6. HOROWITZ, M., GALE, R.P., SONDEL, P.M., GOLDMAN, J.M., KERSEY, J., KOLB, H.J., RIMM, A.A., RINGDEN, O., ROZMAN, C. and SPECK, B., Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555-562 (1990).
7. K MHC gene expression in AKR mouse thymoma. Cell Immunol., 136, 80-94 (1991).
8. LOPEZ-NEVOT, M.A., GARCIA, E., PAREJA, E., BONAL, F.J., MARTIN, J., RUIZ-CABELLO, F. and GARRIDO, F.J., Differential expression of HLA class I and II antigens in primary and metastatic melanomas. Immunogenetics, 13, 219-227 (1986).
9. MATSUMURA, Y. and TARIN, D., Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet, 340, 1053-1058 (1992).
10. MIYAKE, K., WEISSMAN, I.L., GREENBERGER, J.S. and KINCADE, P.W., Evidence for a role of the intesrin VLA-4 in lympho-hemopoiesis. J. exp. Med., 173, 599-607 (1991).
11. MOSCOVITCH, M. and SLAVIN, S., Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. J. Immunol. 132, 997-1000 (1984).
12. NORRIS, D.A., Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. J. invest. Dermatol., 95, 111S-120S (1990).
13. RAZI-WOLF, Z., FREEMAN, G.J., CALVIN, F., BENACERRAF, B., NADLER, L.M. and REISER, H., Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc. nat. Acad. Sci. (Wash.), 89, 4210-4914 (1992).
14. SLAVIN, S., ACKERSTEIN, A., WEISS, L., NAGLER, A., OR, R. and NAPARSTEK, E., Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest., 10, 221-227 (1992).
15. SLAVIN, S., NAPARSTEK, E., NAGLER, A., ACKERSTEIN, A., SAMUEL, S., KAPELUSHNIK, J., BRAUTBAR, C, and OR, R., Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post atloeeneic bone marrow transplantation. Blood, 87, 2195-2204 (1996).
16. SLAVIN, S., WEISS, L., MORECKI, S. and WEINGENSBERG, M., Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol. Immunother., 11, 155-158 (1981).
17. TAKEI, , F., Inhibition of mixed lymphocyte response by a rat monoclonal antibody to a novel murine lymphocyte activation antigen (mala-2). J. Immunol., 134, 1403-1407 (1985).
18. TROWBRIDGE, I.S., LESLEY, J.,
19. SCHULTE, R., HYMAN, R. and TROTTER, J., Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphoid tissues. Immunogenetics, 15, 299-312 (1982).
20. TRUITT, R.L. and ATASOYLU, A.A., Impact of pretransplant conditioning and donor T cells on chimerism. araft-versus-host disease, graft-vs-leukemia reactivity, and tolerance after bone marrow transplantation. Blood, 77, 2515-2523 (1991).
21. VOURKA-KARUSSIS, U., KARUSSIS, D., ACKERSTEIN, A. and SLAVIN, S., Enhancement of graft versus leukemia effect (GVL) with recombinant human interleukin 2 (rIL-2) following bone marrow transplantation in a murine model for acute myeloid leukemia in SJL/J mice. Exp. Hematol., 23, 196-201 (1995).
22. WEBER, J.S., JAY, G., TANAKA, K. and ROSENBERG, S.A., Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection. J. exp. Med., 166, 1716-1733 (1987).
23. ZETTER, B.R., Adhesion molecules in tumor metastasis. Semin. Cancer Biol., 4, 219-229 (1993).